Main > > >RHEUMATOLOGY.

---

Ankylosing Spondylitis. TREAT.: InflixiMAb axxq BioSimilar.
USA Approval Date: 2019. 12.06.
(*) Company; TradeMark & Web-Site Avai-
lable on Request.
UpDate: 2020. 04.11.




Ankylosing Spondylitis. TREAT.: InflixiMAb dyyb BioSimilar.
USA Approval Date: 2016. 04.05.
USA Availability : 2016. 10.17.
Approved in : AU, BR, EU, USA.
(*) Company & TradeMarks Available on
Request.
UpDate: 2017. 12.15.




Ankylosing Spondylitis. TREAT.: InflixiMAb qbtx BioSimilar.
chimeric human-murine MAb against tumor necrosis factor.
USA Approval Date: 2017. 12.13.
(*) Company & TradeMark Available on
Request.
UpDate: 2017. 12.15.




Ankylosing Spondylitis. TREAT.:
Upadacitinib Tablets.
EU CE Mark Date: 2021. 01.25.
(*) Company; Patents; TradeMark & Web-
Site Available on Request.
UpDate: 2021. 03.06.




Dupuytrens Disease. TREAT.: Anti-TNF
MAb. AdalimuMAb.
Status: Phase IIB.
(*) Company; Patents & Web-Site Avai-
lable on Request.
UpDate: 2018. 09.03.




Eosinophilic Granulomatosis with PolyAngiitis (EGPA).
TREAT.: MepolizuMAb SubCutaneous Inj.
IL-5 AntAgonist.
USA Approval Date: 2017. 12.12.
(*) Company; TradeMark & Web-Site Avai-
lable on Request.
UpDate: 2017. 12.13.




Gout. Flares Prophylaxis: Colchicine
0.6 mg/5 ml Oral Solution.
USA Approval Date: 2019. 01.30.
USA Launch Date: 2020. 02.26.
(*) Company; Patents; TradeMark & Web-
Site Available on Request.
UpDate: 2020. 05.01.




Odiopathic Inflammatory Myopathy. DIAG.
USA Approval Date: 2018. 08.14.
(*) Company : Inova Diagnostics
TradeMark: QUANTA Flash® HMGCR
UpDate: 2018. 08.15.




Orthopaedics>Hand OsteoArthritis (OA) [Thumb CarpoMetaCarpal (CMC) OsteoAr- thritis (OA)]. Pain. Treat.: Shaped Allograft Implant.
USA Launch Date: 2019. 07.10.
(*) Companies; Patents; TradeMark &
Web-Site Available on Request.
UpDate: 2020. 04.22.




Polyarticular Juvenile Idiopathic Arthritis (PJIA). Treat.:
TocilizuMAb IntraVenous (IV) Formula-
tion.
USA Approval Date: 2013. 04.30.
(*) Company; TradeMark & Web-Site
Available on Request.
UpDate: 2018. 05.15.




Polyarticular Juvenile Idiopathic Arthritis (PJIA). Treat.:
TocilizuMAb SubCutaneous (SC) Formula-
tion.
USA Approval Date: 2018. 05.14.
(*) Company; Patents; TradeMark & Web-
Site Available on Request.
UpDate: 2018. 05.15.




Psoriatic Arthritis. TREAT.: Apremilast
Tablets.
Oral PDE-4 Inhibitor.
CA Approval Date : 2020. 02.12.
EU Approval Date : 2015. 01.15.
JP Approval Date : 2016. 12.20.
USA Approval Date: 2014. 03.21.
(*) Company; Patents; TradeMark & Web-
Site Available on Request.
UpDate: 2020. 04.11.




Psoriatic Arthritis. TREAT.: InflixiMAb
axxq BioSimilar.
USA Approval Date: 2019. 12.06.
(*) Company; TradeMark & Web-Site Avai-
lable on Request.
UpDate: 2020. 04.11.




Psoriatic Arthritis. TREAT.: InflixiMAb dyyb BioSimilar.
USA Approval Date: 2016. 04.05.
USA Availability: 2016. 10.17.
(*) Company & TradeMarks Available on
Request.
UpDate: 2017. 12.15.




Psoriatic Arthritis. TREAT.: InflixiMAb qbtx BioSimilar.
chimeric human-murine MAb against tumor necrosis factor.
USA Approval Date: 2017. 12.13.
(*) Company & TradeMark Available on
Request.
UpDate: 2017. 12.15.




Psoriatic Arthritis. TREAT.: IxekizuMAb injection 80 mg/mL.
USA Approval Date: 2017. 12.01.
(*) Company & TradeMark Available on
Request.
UpDate: 2017. 12.05.




Psoriatic Arthritis. TREAT.: Tofacitinib 5 mg Twice Daily (BID) & ER 11 mg Once Daily (QD) of adult patients who have had an inadequate response or intolerance to methotrexate or other disease-modifying antirheumatic drugs (DMARDs).
Janus Kinase (JAK) Inhibitor.
USA Approval Date: 2017. 12.14.
(*) Company & TradeMark Available on
Request.
UpDate: 2017. 12.15.




Psoriatic Arthritis. TREAT.: Upadaciti-
nib Tablets.
EU CE Mark Date: 2021. 01.25.
(*) Company; Patents; TradeMark & Web-
Site Available on Request.
UpDate: 2021. 03.06.




Rheumatoid Arthritis. TREAT.:
Baricitinib.
JAK Inhibitor.
EU Approval Date: 2017. 02.13.
JP Approval Date: 2017. 07.03.
USA Approval Date: 2018. 06.01.
(*) Company; Patents & TradeMark Avai-
lable on Request.
UpDate: 2018. 06.02.




Rheumatoid Arthritis. TREAT.:
InflixiMAb axxq BioSimilar.
USA Approval Date: 2019. 12.06.
(*) Company; TradeMark & Web-Site Avai-
lable on Request.
UpDate: 2020. 04.11.




Rheumatoid Arthritis. TREAT.: InflixiMAb dyyb BioSimilar.
USA Approval Date: 2016. 04.05.
USA Availability : 2016. 10.17.
(*) Company & TradeMarks Available on
Request.
UpDate: 2017. 12.15.




Rheumatoid Arthritis. TREAT.: InflixiMAb qbtx BioSimilar.
chimeric human-murine MAb against tumor necrosis factor.
USA Approval Date: 2017. 12.13.
(*) Company & TradeMark Available on
Request.
UpDate: 2017. 12.15.




Rheumatoid Arthritis. TREAT.: Tofacitinib ER Tablet.
Janus Kinase (JAK) Inhibitor.
CN Approval Date: 2017. 03.15.
EU Approval Date: 2017. 03.27.
USA Approval Date: 2016. 02.23.
(*) Company & TradeMark Available on
Request.
UpDate: 2017. 12.15.




Rheumatoid Arthritis. TREAT.:
Upadacitinib Tab.
Janus Kinase (JAK) Inhibitor.
EU Approval Date : 2019. 12.18.
USA Approval Date: 2019. 08.16.
(*) Company; Patents; TradeMark & Web-
Site Available on Request.
UpDate: 2020. 02.11.




Tumor Induced Osteomalacia (TIO). Treat.
BurosuMAb.
USA Approval Date: 2020. 06.18.
(*) Company; Patent; TradeMark & Web-
Site Available on Request.
UpDate: 2021. 02.28


>RHEUMATOLOGY.'s products
This section has no products